Publication: The bioactive peptide SL-13R expands human umbilical cord blood hematopoietic stem and progenitor cells in vitro
1
Issued Date
2021-04-01
Resource Type
ISSN
14203049
Other identifier(s)
2-s2.0-85105230126
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Molecules. Vol.26, No.7 (2021)
Suggested Citation
Takenobu Nii, Katsuhiro Konno, Masaki Matsumoto, Kanit Bhukhai, Suparerk Borwornpinyo, Kazuhiro Sakai, Suradej Hongeng, Daisuke Sugiyama The bioactive peptide SL-13R expands human umbilical cord blood hematopoietic stem and progenitor cells in vitro. Molecules. Vol.26, No.7 (2021). doi:10.3390/molecules26071995 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/76218
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
The bioactive peptide SL-13R expands human umbilical cord blood hematopoietic stem and progenitor cells in vitro
Abstract
Hematopoietic stem and progenitor cell (HSPC) transplantation is a curative treatment of hematological disorders that has been utilized for several decades. Although umbilical cord blood (UCB) is a promising source of HSPCs, the low dose of HSPCs in these preparations limits their use, prompting need for ex vivo HSPC expansion. To establish a more efficient method to expand UCB HSPCs, we developed the bioactive peptide named SL-13R and cultured UCB HSPCs (CD34+ cells) with SL-13R in animal component-free medium containing a cytokine cocktail. Following 9 days of culture with SL-13R, the numbers of total cells, CD34+, CD38− cells, and hematopoietic stem cell (HSC)-enriched cells were significantly increased relative to control. Transplantation of cells cultured with SL-13R into immunodeficient NOD/Shi-scid/IL-2Rγ knockout mice confirmed that they possess long-term reconstitution and self-renewal ability. AHNAK, ANXA2, and PLEC all interact with SL-13R. Knockdown of these genes in UCB CD34+ cells resulted in reduced numbers of hematopoietic colonies relative to SL-13R-treated and non-knockdown controls. In summary, we have identified a novel bioactive peptide SL-13R promoting expansion of UCB CD34+ cells with long-term reconstitution and self-renewal ability, suggesting its clinical use in the future.